Markets News

Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.

Reddit Stock Jumps as Analysts Flag Strong Ad Momentum
Markets Daniel Marsh

Reddit Stock Jumps as Analysts Flag Strong Ad Momentum

Reddit shares surged 6.6% after two analyst firms cited stronger ad demand and raised revenue forecasts, with Cleveland Research noting 45% of advertisers beat ROI targets in Q2.

RDDT SNAP PINS META GOOGL
Autozi Stock Surges 400% After Reverse Split, But Going Concern Warning Looms
Markets Daniel Marsh

Autozi Stock Surges 400% After Reverse Split, But Going Concern Warning Looms

Autozi shares jumped over 400% to $5.69 after a reverse split, but the company reported a 63% revenue decline and warned of substantial doubt about its ability to continue.

AZI
Redwire Stock Drops 6.5% on $500M ATM Offering Plan
Markets Daniel Marsh

Redwire Stock Drops 6.5% on $500M ATM Offering Plan

Redwire Corp shares fell 6.5% to $17.37 after filing a $500M at-the-market stock program, raising dilution concerns despite record backlog and strong revenue growth.

RDW RKLB ASTS PL
GSK's $10.6B Nuvalent Bid Drives Stock Near Offer Price
Markets Daniel Marsh

GSK's $10.6B Nuvalent Bid Drives Stock Near Offer Price

Nuvalent shares jumped 38.9% to $122.93 after GSK's $10.6 billion buyout offer, as investors bet on the deal closing with two lead lung-cancer drugs under FDA review.

NUVL GSK
AT&T Shares Edge Up as $45B Payout Plan and 2026 Guidance Hold Steady
Markets Daniel Marsh

AT&T Shares Edge Up as $45B Payout Plan and 2026 Guidance Hold Steady

AT&T shares edged up pre-market after reaffirming 2026 targets and a $45B+ payout plan, providing a cash-flow marker as satellite broadband competition looms.

T TMUS VZ
GSK Acquires Nuvalent for $10.6B in Oncology Push Ahead of HIV Patent Cliff
Markets Daniel Marsh

GSK Acquires Nuvalent for $10.6B in Oncology Push Ahead of HIV Patent Cliff

GSK buys Nuvalent for $10.6B, paying a 40% premium, to strengthen its oncology portfolio and offset upcoming HIV drug patent losses.

GSK NUVL AZN
Pfizer Stock Dips Despite FDA Nod for Hemophilia Drug Hympavzi
Markets Daniel Marsh

Pfizer Stock Dips Despite FDA Nod for Hemophilia Drug Hympavzi

Pfizer shares fell premarket despite FDA approval for hemophilia drug Hympavzi, as investors focus on slower obesity drug progress and pipeline challenges.

PFE NVO LLY SPY XLV
Grab's Growth Strategy in Focus with New Singapore Merchant Program and Taiwan Entry
Markets Daniel Marsh

Grab's Growth Strategy in Focus with New Singapore Merchant Program and Taiwan Entry

Grab shares remained near flat in pre-market trading after announcing a Singapore merchant program and Taiwan partner commitments, as investors assess growth initiatives against regulatory and margin risks.

GRAB
CCSC Surges Premarket as Nasdaq Compliance Deadline Nears
Markets Daniel Marsh

CCSC Surges Premarket as Nasdaq Compliance Deadline Nears

CCSC Technology International Holdings surged 315% in premarket trading to $1.99, approaching Nasdaq's $1 minimum bid price just days before its June 15 compliance deadline.

CCTG
Core AI Stock Skyrockets 474% in Premarket on AI Rally
Markets Daniel Marsh

Core AI Stock Skyrockets 474% in Premarket on AI Rally

Core AI Holdings shares jumped 474% in premarket trading on heavy volume, riding a wave of AI stock momentum, but the company faces a going-concern warning and significant funding challenges.

AI
Plug Power Stock Hovers Near $3 as Shareholder Meeting Looms
Markets Daniel Marsh

Plug Power Stock Hovers Near $3 as Shareholder Meeting Looms

Plug Power stock hovers near $3.19 as traders focus on cash and dilution risks ahead of the June 11 shareholder meeting.

PLUG BE BLDP
Nu Holdings Shares Edge Higher on $1B Buyback, Credit Worries Linger
Markets Daniel Marsh

Nu Holdings Shares Edge Higher on $1B Buyback, Credit Worries Linger

Nu Holdings shares edged up 0.7% in pre-market trading Tuesday, recovering slightly from Monday's 3.1% drop, as investors weighed a $1 billion buyback against ongoing concerns over credit costs, margin compression, and a CFO transition.

NU